Literature DB >> 17509624

Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil.

Raquel L F Teixeira1, Antonio B Miranda, Antonio G Pacheco, Márcia Q P Lopes, Joseane Fonseca-Costa, Marcelo F Rabahi, Hedi M Melo, Afrânio L Kritski, Fernanda C Q Mello, Philip N Suffys, Adalberto R Santos.   

Abstract

Arylamine N-acetyltranferase 2 is the main enzyme responsible for the isoniazid metabolization into hepatotoxic intermediates and the degree of hepatotoxicity severity has been attributed to genetic variability in the NAT2 gene. The main goal of this study was to describe the genetic profile of the NAT2 gene in individuals from two different regions of Brazil: Rio de Janeiro and Goiás States. Therefore, after preparation of DNA samples from 404 individuals, genotyping of the coding region of NAT2 was performed by direct PCR sequencing. Thirteen previously described SNPs were detected in these Brazilian populations, from which seven: 191 G>A; 282 C>T; 341 T>C; 481 C>T; 590 G>A; 803 A>G and 857 G>A are the most frequent in other populations. The presence of so-called ethnic-specific SNPs in our population is in accordance with the Brazilians' multiple ancestry. Upon allele and genotype analysis, the most frequent NAT2 alleles were respectively NAT2*5B (33%), NAT2*6A (26%) and NAT2*4 (20%) being NAT2*5/*5 the more prevalent genotype (31.7%). These results clearly demonstrate the predominance in the studied Brazilian groups of NAT2 alleles associated with slow over the fast and intermediate acetylator genotypes. Additionally, in Rio de Janeiro, a significantly higher frequency of intermediate acetylation status was found when compared to Goiás (42.5% versus 25%) (p=0.05), demonstrating that different regions of a country with a population characterized by a multi-ethnic ancestry may present a large degree of variability in NAT2 allelic frequencies. This finding has implications in the determination of nationwide policies for use of appropriate anti-TB drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509624     DOI: 10.1016/j.mrfmmm.2007.03.015

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  6 in total

1.  Study of NAT2 genetic polymorphism in West African subjects: example of an healthy non-smoker Senegalese population.

Authors:  A Touré; C Diop; M Cabral; M Fall; M Lhermitte; A Diouf; F Broly; D Allorge
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

2.  Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil.

Authors:  L G Possuelo; J A Castelan; T C de Brito; A W Ribeiro; P I Cafrune; P D Picon; A R Santos; R L F Teixeira; T S Gregianini; M H Hutz; M L R Rossetti; A Zaha
Journal:  Eur J Clin Pharmacol       Date:  2008-04-18       Impact factor: 2.953

3.  Physiogenomic analysis of the Puerto Rican population.

Authors:  Gualberto Ruaño; Jorge Duconge; Andreas Windemuth; Carmen L Cadilla; Mohan Kocherla; David Villagra; Jessica Renta; Theodore Holford; Pedro J Santiago-Borrero
Journal:  Pharmacogenomics       Date:  2009-04       Impact factor: 2.533

4.  Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data.

Authors:  Audrey Sabbagh; Pierre Darlu; Michel Vidaud
Journal:  BMC Med Genet       Date:  2009-12-31       Impact factor: 2.103

5.  Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity.

Authors:  James C Sacco; Mahmoud Abouraya; Alison Motsinger-Reif; Steven H Yale; Catherine A McCarty; Lauren A Trepanier
Journal:  Pharmacogenet Genomics       Date:  2012-10       Impact factor: 2.089

6.  Interethnic diversity of NAT2 polymorphisms in Brazilian admixed populations.

Authors:  Jhimmy Talbot; Luiz Alexandre V Magno; Cinthia V N Santana; Sandra M B Sousa; Paulo R S Melo; Ronan X Correa; Giuliano Di Pietro; Fabrício Rios-Santos
Journal:  BMC Genet       Date:  2010-10-05       Impact factor: 2.797

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.